Prior to the creation of Preora, Vadim Backman’s Northwestern University laboratory had received close to $20 million in NIH and NSF grant funding for the development of the core PWS technology, and an additional $6.9 million in fast track SBIR/STTR grants to support the product and process development for commercialization. The extraordinarily high level of grant funding serves as evidence of the clinical potential of the PWS technology platform.

Preora is currently fundraising and has recently secured $1.75 million of a targeted $3 – $4 million in outside private funding to provide business planning support, complete the lung test verification studies and to purchase the long lead time equipment required to build out the Preora Operating Lab.

The company is planning to initiate a Series A raise in 2H 2017 with a goal to attain $10 -$12 million by the end of 2017. The funds will be used to complete the pivotal clinical studies for the lung test, gain CLIA lab certification, initiate clinical validation studies for the colon test and to support the launch of the lung test.
Please contact John Hart, President and CEO at to indicate interest or learn more about investment opportunities.

Recently Completed Milestones

  • Completed PWS Microscope High-Throughput Validation (Q1 2015)
  • Successful Pre-submission Meetings with the FDA (Q1 and Q4 2015)
  • Completed Lung Test Clinical Optimization Studies (Diagnostic Verification) (Q3 2015)
  • Patent Application filed for New “high-quality” slide preparation process and device (Q1 2016)
  • Received NIH SBIR research grant for $1.5 million for ongoing Lung Cancer test clinical studies(Q3 2016)
  • Raised $1.75 million private funds to support the CLIA lab build out and validation (Q3 2016)

Future Key Milestones

  • Initiate Lung Test Multisite Clinical Validation Studies (Q3 2016)
  • Complete the build out the Preora Operating Lab (Q4 2016)
  • ISO Certification for our Product Development Laboratory (Q4 2016)
  • CLIA Certification for our Operating Laboratory (Q1 2017)
  • Market launch of the LDT lung test (2017)

Important Notices & Disclaimer

This website has been prepared solely for informational purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell securities of Preora or any security or instrument or to participate in any trading strategy. No sale of securities will be made in any jurisdiction in which the offer, solicitation or sale is not authorized or to any person to whom it is unlawful to make the offer, solicitation or sale.  If any such offer of securities is made by Preora, it will be made pursuant to a definitive private placement memorandum (the “Memorandum”) prepared by Preora that contains material information not contained in this website and to which prospective investors will be referred. Any decision to invest in securities should be made solely in reliance upon the Memorandum.

No representation or warranty (express or implied) is made or can be given with respect to the accuracy or completeness of the information in this website, or that any offer of securities will conform to the terms described in this website. Certain assumptions have been made regarding the financial performance information included in this website, and such performance information is presented by way of example only. No representation is made that the performance presented will be achieved by Preora, or that every assumption made in achieving, calculating or presenting the financial performance information in this website has been considered or stated in preparing this website. Any changes to assumptions that may have been made in preparing the website could have a material impact on the investment returns that are included in this website by way of example.  Financial projections may not be indicative of future performance or investment returns, and prospective investors should not view the projections in this website as an indicator of the future performance of Preora. An investment in Preora is speculative and involves significant risks, including the risk of loss of the entire investment.  The risks include, but are not limited to the following: the uncertainty of the national economy; economic conditions generally and the healthcare market specifically.